Another great way to get the giggles going is by reading funny Thanksgiving quotes to one another. These funny Thanksgiving quotes capture the humor in preparing a big meal, spending time with ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

Throughout the world, an estimated 800 million people consider cassava root a staple part of their diet. This starchy tuber—also known as yuca, Brazilian arrowroot, and manioc—first originated in ...

Studies that once seemed to support the drug, simufilam, have been called into question, leading to retractions from scientific journals and resignations of top officials at Cassava Sciences ...

From Scream to The Frighteners, keep reading for 40 funny Halloween movies to watch on Netflix, Max and more. The 100 Best Halloween Movies of All Time Philippe Bossé/Paramount Pictures According ...

Who’s in it? Jemaine Clement, Taika Waititi, Jonathan Brugh Rating: R Directed by Jemaine Clement and Taika Waititi, this mockumentary-style flick is quirky, incredibly funny and so smart. In the ...

Please verify your email address. There's a common perception that the emoji on iPhones (and other Apple devices) are superior to those on Android phones, but that isn't the case. Anyone who's ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Although Nigeria is ranked number one in cassava production globally, she imported about $54,200 in cassava in 2022, becoming the 121st largest importer of cassava in the world. This was disclosed ...

A former Alzheimer’s researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...